Related references
Note: Only part of the references are listed.Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Hussein A. Tawbi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Histology-based molecular profiling improves mutation detection for advanced thyroid cancer
Markus Eszlinger et al.
GENES CHROMOSOMES & CANCER (2021)
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
Amod A. Sarnaik et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study
Ines Pires da Silva et al.
LANCET ONCOLOGY (2021)
Evolution of delayed resistance to immunotherapy in a melanoma responder
David Liu et al.
NATURE MEDICINE (2021)
Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion
Suchit Jhunjhunwala et al.
NATURE REVIEWS CANCER (2021)
Acquired Resistance to Immune Checkpoint Inhibitors
Adam J. Schoenfeld et al.
CANCER CELL (2020)
Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade
Davis Y. Torrejon et al.
CANCER DISCOVERY (2020)
Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8+ T Cells in Non-Melanoma Cancers Compared to Melanoma
Aishwarya Gokuldass et al.
CANCERS (2020)
Acquired resistance to cancer immunotherapy
Arianna Draghi et al.
SEMINARS IN IMMUNOPATHOLOGY (2019)
Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy.
Asim Amin et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression
R. Andersen et al.
ANNALS OF ONCOLOGY (2018)
Systematic Functional Annotation of Somatic Mutations in Cancer
Patrick Kwok-Shing Ng et al.
CANCER CELL (2018)
Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions
Antje Sucker et al.
NATURE COMMUNICATIONS (2017)
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Moshe Sade-Feldman et al.
NATURE COMMUNICATIONS (2017)
Near-optimal probabilistic RNA-seq quantification
Nicolas L. Bray et al.
NATURE BIOTECHNOLOGY (2016)
Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T-Cells, Which Dampen CD8+ T-cell Antitumor Reactivity
Marco Donia et al.
CANCER RESEARCH (2015)
Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma
Ana B. del Campo et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Characterization and Comparison of Standard' and Young' Tumour-Infiltrating Lymphocytes for Adoptive Cell Therapy at a Danish Translational Research Institution
M. Donia et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2012)
Fast and accurate short read alignment with Burrows-Wheeler transform
Heng Li et al.
BIOINFORMATICS (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Expression of HLA class I antigens and restoration of antigen-specific ctl response in melanoma cells following 5-aza-2′-deoxycytidine treatment
A Serrano et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Share Paper
